NCT00603447 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 44
- group Id
- BG007
- value
- 84
- units
- Participants
- groups
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 10 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG000
- title
- 1: CFZ 15 mg/m² + LEN 10 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 15 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG001
- title
- 2: CFZ 15 mg/m² + LEN 15 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG002
- title
- 3: CFZ 15 mg/m² + LEN 20 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG003
- title
- 4: CFZ 20 mg/m² + LEN 20 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG004
- title
- 5: CFZ 20 mg/m² + LEN 25 mg
- description
- Treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG005
- title
- 6: CFZ 20/27 mg/m² + LEN 25 mg
- description
- In the Expansion portion, treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG006
- title
- 7: CFZ 20/27 mg/m² + LEN 25 mg
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.65
- value
- 64.7
- group Id
- BG001
- spread
- 12.11
- value
- 64.2
- group Id
- BG002
- spread
- 7.74
- value
- 55.4
- group Id
- BG003
- spread
- 6.68
- value
- 61.7
- group Id
- BG004
- spread
- 9.31
- value
- 57.7
- group Id
- BG005
- spread
- 7.85
- value
- 65.4
- group Id
- BG006
- spread
- 10.75
- value
- 62.4
- group Id
- BG007
- spread
- 9.86
- value
- 61.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 36
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 9
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 3
- title
- Asian/Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 34
- group Id
- BG007
- value
- 64
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 7
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 23
- group Id
- BG007
- value
- 33
- title
- 0 (Fully active)
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 46
- title
- 1 (Restrictive but ambulatory)
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 5
- title
- 2 (Ambulatory but unable to work)
- description
- Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, no self-care, confined to bed or chair.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 2
- upper Limit
- 4
- value
- 3.3
- group Id
- BG001
- lower Limit
- 2
- upper Limit
- 5
- value
- 2.4
- group Id
- BG002
- lower Limit
- 2
- upper Limit
- 15
- value
- 3.9
- group Id
- BG003
- lower Limit
- 0
- upper Limit
- 9
- value
- 2.8
- group Id
- BG004
- lower Limit
- 1
- upper Limit
- 22
- value
- 3.5
- group Id
- BG005
- lower Limit
- 1
- upper Limit
- 12
- value
- 4.3
- group Id
- BG006
- lower Limit
- 0
- upper Limit
- 16
- value
- 2.8
- group Id
- BG007
- lower Limit
- 0
- upper Limit
- 22
- value
- 3.1
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time Since Diagnosis
- unit Of Measure
- years
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 44
- group Id
- BG007
- value
- 84
- units
- Participants
- groups
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 10 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG000
- title
- 1: CFZ 15 mg/m² + LEN 10 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 15 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG001
- title
- 2: CFZ 15 mg/m² + LEN 15 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG002
- title
- 3: CFZ 15 mg/m² + LEN 20 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG003
- title
- 4: CFZ 20 mg/m² + LEN 20 mg
- description
- Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG004
- title
- 5: CFZ 20 mg/m² + LEN 25 mg
- description
- Treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG005
- title
- 6: CFZ 20/27 mg/m² + LEN 25 mg
- description
- In the Expansion portion, treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
- id
- BG006
- title
- 7: CFZ 20/27 mg/m² + LEN 25 mg
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.65
- value
- 64.7
- group Id
- BG001
- spread
- 12.11
- value
- 64.2
- group Id
- BG002
- spread
- 7.74
- value
- 55.4
- group Id
- BG003
- spread
- 6.68
- value
- 61.7
- group Id
- BG004
- spread
- 9.31
- value
- 57.7
- group Id
- BG005
- spread
- 7.85
- value
- 65.4
- group Id
- BG006
- spread
- 10.75
- value
- 62.4
- group Id
- BG007
- spread
- 9.86
- value
- 61.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 18
- group Id
- BG007
- value
- 36
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 48
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 9
- title
- African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 3
- title
- Asian/Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 34
- group Id
- BG007
- value
- 64
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 7
- title
- Hispanic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 23
- group Id
- BG007
- value
- 33
- title
- 0 (Fully active)
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 17
- group Id
- BG007
- value
- 46
- title
- 1 (Restrictive but ambulatory)
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 5
- title
- 2 (Ambulatory but unable to work)
- description
- Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, no self-care, confined to bed or chair.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 2
- upper Limit
- 4
- value
- 3.3
- group Id
- BG001
- lower Limit
- 2
- upper Limit
- 5
- value
- 2.4
- group Id
- BG002
- lower Limit
- 2
- upper Limit
- 15
- value
- 3.9
- group Id
- BG003
- lower Limit
- 0
- upper Limit
- 9
- value
- 2.8
- group Id
- BG004
- lower Limit
- 1
- upper Limit
- 22
- value
- 3.5
- group Id
- BG005
- lower Limit
- 1
- upper Limit
- 12
- value
- 4.3
- group Id
- BG006
- lower Limit
- 0
- upper Limit
- 16
- value
- 2.8
- group Id
- BG007
- lower Limit
- 0
- upper Limit
- 22
- value
- 3.1
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Time Since Diagnosis
- unit Of Measure
- years
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle